Amoxicillin-associated Stevens-Johnson syndrome or toxic epidermal necrolysis: systematic review

References

• Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg. 2016;69(6):e119–e153.
   PubMed Web of Science ®Google Scholar
• Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603–625.
   PubMed Web of Science ®Google Scholar
• Yang MS, Lee JY, Kim J, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS One. 2016; 11(11):e0165933.
   PubMed Web of Science ®Google Scholar
• Hsu DY, Brieva J, Silverberg NB, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811–817.
   PubMed Web of Science ®Google Scholar
• Gilbert M, Scherrer LA. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Ther. 2019;32(1):e12758
   PubMed Web of Science ®Google Scholar
• Wang YH, Chen CB, Tassaneeyakul W, Asian Severe Cutaneous Adverse Reaction Consortium, et al. The medication risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in asians: the major drug causality and comparison with the US FDA label. Clin Pharmacol Ther. 2019;105(1):112–120.
   PubMed Web of Science ®Google Scholar
• Akhavan BJ, Khanna Nr Vijhani P. Amoxicillin [Updated. 2021. Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482250/
   Google Scholar
• Food and Drug Administration. AMOXIL®. Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050542s24,050754s11,050760s10,050761s10lbl.pdf.
   Google Scholar
• Evans J, Hannoodee M, Wittler MA. Clavulanate [Updated 2021 Mar 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538164/
   Google Scholar
• Electronic Medicines Compendium. Amoxicillin 500 mg Capsules BP- Summary of Product. Undesirable effects. Available from: https://www.medicines.org.uk/emc/product/6109/smpc#UNDESIRABLE_EFFECTS.
   Google Scholar
• Schöpf E, Stühmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127(6):839–842.
   PubMedGoogle Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–1285.
   PubMed Web of Science ®Google Scholar
• Korkut M, Bedel C. A case report of Stevens-Johnson syndrome, a dermatological emergency, secondary to amoxicillin-clavulanic acid use. J Pak Assoc Dermatol. 2020;30(3):519–521.
   Google Scholar
• Abou-Elhamd K-EA. Two cases of Stevens-Johnson syndrome following intake of klavox with review of literature. Eur Arch Otorhinolaryngol. 2009;266(8):1327–1330.
   PubMed Web of Science ®Google Scholar
• Barajas-Ochoa A, Montealegre N, Perez-Peralta A. A young man with red eyes, polymorphous rash, and Mucositis-an On-the-Spot Diagnosis. J Gen Intern Med. 2020;35(4):1309–1310.
   PubMed Web of Science ®Google Scholar
• Barea-Jiménez N, Calero J, Molina-Negrón D, et al. Treatment for oral lesions in pediatric patients with Stevens-Johnson's syndrome: A case report and literature review. Int J Paediatr Dent. 2020;30(4):489–496.
   PubMed Web of Science ®Google Scholar
• Barrick C, Macatuno E. Progressive rash, oral lesions, and history of antibiotic use in a 17-Year-Old boy: Stevens-Johnson syndrome: a case report. Clin Pediatr (Phila). 2014;53(11):1101–1105.
   PubMed Web of Science ®Google Scholar
• Carmona AF, Redondo AD, Peña LO, et al. Toxic epidermal necrolysis treated with cyclosporin A. Med Intensiva. 2011;35(7):442–445.
   PubMed Web of Science ®Google Scholar
• Fathallah N, Hanen Z, Slim R, et al. Co-amoxiclav-induced Stevens Johnson syndrome in a child. Pan Afr Med J. 2013;14:38.
   PubMedGoogle Scholar
• Hewitt J, Ormerod AD. Toxic epidermal necrolysis treated with cyclosporin. Clin Exp Dermatol. 1992;17(4):264–265.
   PubMed Web of Science ®Google Scholar
• Khairullah S, Ismail RC. Severe cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysisa, a report of 4 cases seen at UMMC. J Health Transl Med. 2010;13(1):50–58.
   Google Scholar
• Kumar RM, Nyamagoud S, Deshpande K, et al. Amoxicillin induced steven johnson’s syndrome: a case report. J Drug Delivery Ther. 2020;10(4-s):220–222.
   Google Scholar
• Lee Y-Y, Ko J-H, Wei C-H, et al. Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Dermatol Sin. 2013;31(2):78–81.
   Web of Science ®Google Scholar
• Limauro DL, Chan-Tompkins NH, Carter RW, et al. Amoxicillin/Clavulanate-Associated hepatic failure with progression to Stevens-Johnson syndrome. Ann Pharmacother. 1999;33(5):560–564.
   PubMed Web of Science ®Google Scholar
• Massullo RE, Welton WA, Jacobsen E. Toxic epidermal necrolysis: report of two cases. J Am Acad Dermatol. 1988;19(2):358–360.
   PubMed Web of Science ®Google Scholar
• Mori F, Fili L, Barni S, et al. T-cell activation in two cases of Stevens-Johnson syndrome after receiving amoxicillin-clavulanic acid. Pediatr Allergy Immunol. 2017;28(6):602–606.
   PubMed Web of Science ®Google Scholar
• Narasimha G L, P K. Amoxicillin induced toxic epidermal necrolysis. Int J Basic Clin Pharmacol. 2020;9(3):510–512.
   Google Scholar
• Önder E, Güngör A, Celbek G, et al. Geriatrik yaşta amoksisilin kullanımı sonucu gelişen ve hayatı tehtid eden, ağır stevens johnson sendromu [Severe life threatening amoxicillin related stevens johnson syndrome in a geriatric patient]. Turk J Geriatr. 2010;13(1):36–40.
   Google Scholar
• Patel JB, Agrawal P, Soitawala S, et al. Amoxicillin induced toxic epidermal necrolysis (TEN): a case report. Int J Res Med Sci. 2015;3(4):1011–1014.
   Google Scholar
• Rabelink NM, Brakman M, Maartense E, et al. Erythema multiforme versus Stevens-Johnson-syndroom en toxische epidermale necrolyse; belangrijk diagnostisch onderscheid [Erythema multiforme vs. Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction]. Ned Tijdschr Geneeskd. 2003;147(43):2089–2094. ].
   PubMedGoogle Scholar
• Rawte S, Bellary NN, Shiradkar S. Steven Johnson syndrome in pregnancy. MedPulse – Int Med J. 2015;2(11):765–767.
   Google Scholar
• Romańska-Gocka K, Gocki J, Placek W, et al. Stevens johnson syndrome after carbamazepine and SJS/TEN overlap syndrome after amoxicillin: case reports and a review. Arch Med Sci. 2010;6(1):130–134.
   PubMed Web of Science ®Google Scholar
• Sever C, Kulahci Y, Oksuz S, et al. Toxic epidermal necrolysis caused by amoxicillin. J Clin Anal Med. 2011;2(3):121–123.
   Google Scholar
• Srinivasan S, Karthikeyan E, Sivaneswari S, et al. Clinical condition and medication therapy of amoxicillin-induced Stevens-Johnson syndrome: a case report. Aging Med (Milton). 2019;2(4):227–229.
   PubMedGoogle Scholar
• Sugino K, Hebisawa A, Uekusa T, et al. Bronchiolitis obliterans associated with Stevens-Johnson syndrome: histopathological bronchial reconstruction of the whole lung and immunohistochemical study. Diagn Pathol. 2013;8(1):134.
   PubMedGoogle Scholar
• Surbled M, Lejus C, Milpied B, et al. Syndrome de lyell consécutif à l’administration d’amoxicilline chez un enfant de 2 ans. Ann Fr Anesth Réanimation. 1996;15(7):1095–1098.
   PubMedGoogle Scholar
• Unnisa Z, Fareedullah M, Jabeen S, et al. Amoxycillin-clavulanic acid induced stevens johnson syndrome: a pediatric case report. J Young Pharm. 2021;13(1):80–81.
   Web of Science ®Google Scholar
• Zaidi M, Zaidi SK, Bhutto M, et al. Amoxycillin and clavulanic acid induced Stevens-Johnson syndrome: a case report. Excli J. 2017;16:748–751.
   PubMed Web of Science ®Google Scholar
• Sibbald C, Putterman E, Micheletti R, et al. Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatr Dermatol. 2020;37(3):461–466.
   PubMed Web of Science ®Google Scholar
• Adzick NS, Kim SH, Bondoc CC, et al. Management of toxic epidermal necrolysis in a pediatric burn center. Am J Dis Child. 1985;139(5):499–502.
   PubMedGoogle Scholar
• Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002;6(3):225–228.
   PubMedGoogle Scholar
• Bang D, Shah T, Thakker D, et al. Drug-induced Stevens-Johnson syndrome: case series from tertiary care centre in Gujarat. Pharmacoepidemiol Drug Saf. 2012;21(4):384–395.
   PubMed Web of Science ®Google Scholar
• B, Salem C, Badreddine A, Belajouza O, et al. Toxic epidermal necrolysis: a retrospective analysis of 17 cases from Central Tunisia. Pan Afr Med J. 2014;19:269.
   PubMedGoogle Scholar
• Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36(3):218–222.
   PubMed Web of Science ®Google Scholar
• Gacto ‐Sanchez P, Pereyra ‐Rodriguez JJ, Carbajal J, et al. Toxic epidermal necrolysis treatment without immunosuppressive therapy in a burn Centre: a series of 10 cases. J Eur Acad Dermatol Venereol. 2018;32(2):e66–e68.
   PubMed Web of Science ®Google Scholar
• Gerdts B, Vloemans A, Kreis RW. Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre. J Eur Acad Dermatol Venereol. 2007;21(6):781–788.
   PubMed Web of Science ®Google Scholar
• Ioannides D, Vakali G, Chrysomallis F, et al. Toxic epidermal necrolysis: a study of 22 cases. J Eur Acad Dermatol Venerol. 1994;3(3):266–275.
   Google Scholar
• Koh MJ-A, Tay Y-K. Stevens-Johnson syndrome and toxic epidermal necrolysis in asian children. J Am Acad Dermatol. 2010;62(1):54–60.
   PubMed Web of Science ®Google Scholar
• Koštál M, Bláha M, Lánská M, et al. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases. J Clin Apher. 2012;27(4):215–220.
   PubMed Web of Science ®Google Scholar
• Mori F, Fili L, Barni S, et al. Sensitization to amoxicillin/clavulanic acid may underlie severe rashes in children treated for infectious mononucleosis. J Allergy Clin Immunol Pract. 2019;7(2):728–731.e1.
   PubMed Web of Science ®Google Scholar
• Nassar A, Eid E, Bastawi Y, et al. Efficacy of intravenous immunoglobulins for treatment of Stevens-Johnson syndrome, toxic epidermal necrolysis and their overlap. Gulf J Dermatol Venerol. 2010;17(1):20–31.
   Google Scholar
• Noskin GA, Patterson R. Outpatient management of Stevens-Johnson syndrome: a report of four cases and management strategy. Allergy Asthma Proc. 1997;18(1):29–32.
   PubMed Web of Science ®Google Scholar
• Olson D, Abbott J, Lin C, et al. Characterization of children with recurrent episodes of stevens johnson syndrome. J Pediatric Infect Dis Soc. 2017;6(3):e140–e143.
   PubMed Web of Science ®Google Scholar
• Sato S, Kanbe T, Tamaki Z, et al. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Int. 2018;60(8):697–702.
   PubMed Web of Science ®Google Scholar
• Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149(2):203–213.e2.
   PubMed Web of Science ®Google Scholar
• Struck MF, Illert T, Schmidt T, et al. Secondary abdominal compartment syndrome in patients with toxic epidermal necrolysis. Burns. 2012;38(4):562–567.
   PubMed Web of Science ®Google Scholar
• Teo L, Tay YK, Liu TT, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Efficacy of intravenous immunoglobulin and a review of treatment options. Singapore Med J. 2009;50(1):29–33.
   PubMed Web of Science ®Google Scholar
• Ward DJ, Krzeminska EC, Tanner NSB. Treatment of toxic epidermal necrolysis and a review of six cases. Burns. 1990;16(2):97–104.
   PubMed Web of Science ®Google Scholar
• Alajaji A, C, Shekaran J, M, Aldhabbah O, et al. Toxic epidermal necrolysis (TEN)/Stevens-Johnson syndrome (SJS) epidemiology and mortality rate at king fahad specialist hospital (KFSH) in qassim region of Saudi Arabia: a retrospective study. Dermatol Res Pract. 2020;2020:e7524726.
   PubMed Web of Science ®Google Scholar
• Lin Y-F, Yang C-H, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis. 2014;58(10):1377–1385.
   PubMed Web of Science ®Google Scholar
• Su P, Aw CWD. Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study. Int J Dermatol. 2014;53(11):1339–1345.
   PubMed Web of Science ®Google Scholar
• Van Batavia JP, Chu DI, Long CJ, et al. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017;13(5):490.e1–e7.
   PubMed Web of Science ®Google Scholar
• Wang L, Mei X. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 88 chinese patients. Chin Med J (Engl). 2017;130(9):1062–1068.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Outpatient antibiotic prescriptions — United States, 2020. Available from: https://www.cdc.gov/antibiotic-use/pdfs/Annual-Report-2020-H.pdf.
   Google Scholar
• Pulcini C. Amoxicillin Amoxicillin dosing recommendations are very different in European countries: a cross-sectional survey. Clin Microbiol Infect. 2017;23(6):414–415.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. AUGMENTIN® (amoxicillin/clavulanate potassium). Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050575s037550597s044050725s025050726s019lbl.pdf.
   Google Scholar
• Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007;60(1):121–126.
   PubMed Web of Science ®Google Scholar
• Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.
   PubMed Web of Science ®Google Scholar
• Chang WC, Abe R, Anderson P, et al. SJS/TEN 2019: from science to translation. J Dermatol Sci. 2020;98(1):2–12.
   PubMed Web of Science ®Google Scholar
• Hazin R, Ibrahimi OA, Hazin MI, et al. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008;40(2):129–138.
   PubMed Web of Science ®Google Scholar
• Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol. 1995;155(1):462–472.
   PubMed Web of Science ®Google Scholar
• Pejčić AV. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases. Int J Dermatol. 2021;60(1):12–24.
   PubMed Web of Science ®Google Scholar
• Milosavljević MN, Pejčić AV, Milosavljević JZ. A review of published cases of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of acetaminophen. Cutan Ocul Toxicol. 2021;40(3):280–292.
   PubMed Web of Science ®Google Scholar
• Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al. EuroSCAR study group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15(14):1843–1848. ;
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Dunant A, Mockenhaupt M. Epidermal necrolysis, ocular complications, and "cold medicines". J Allergy Clin Immunol Pract. 2018;6(2):703–704.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Lim H, Park SY, et al. Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen. Asia Pac Allergy. 2014;4(1):68–72.
   PubMedGoogle Scholar
• Yang MS, Lee JY, Kim J, et al. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in korea. J Allergy Clin Immunol Pract. 2020;8(2):690–695.
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33(1):10–16.
   PubMed Web of Science ®Google Scholar
• Ferrara P, Cutrona C, Sbordone A. Which treatment for upper respiratory tract infections? Ital J Pediatr. 2015;41(S2):A31.
   PubMedGoogle Scholar
• Cotton M, Innes S, Jaspan H, et al. Management of upper respiratory tract infections in children. S Afr Fam Pract (2004). 2008;50(2):6–12.
   PubMedGoogle Scholar
• Rashid M, Kashyap A, Undela K. Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. Int J Dermatol. 2019;58(9):1014–1022.
   PubMed Web of Science ®Google Scholar
• Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clinic Rev Allerg Immunol. 2018;54(1):147–176.
   PubMed Web of Science ®Google Scholar
• Kumar R, Das A, Das S. Management of Stevens-Johnson Syndrome-Toxic epidermal necrolysis: Looking beyond guidelines!. Indian J Dermatol. 2018;63(2):117–124.
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and Meta-analysis. JAMA Dermatol. 2017;153(6):514–522.
   PubMed Web of Science ®Google Scholar
• Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–493.
   PubMed Web of Science ®Google Scholar
• Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–853.
   PubMed Web of Science ®Google Scholar
• Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138(11):2315–2321.
   PubMed Web of Science ®Google Scholar
• Krajewski A, Maciejewska-Markiewicz D, Jakubczyk K, et al. Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in toxic epidermal necrolysis, Steven-Johnsons syndrome, and TEN/SJS overlap - metanalysis and metaregression of observational studies. Burns. 2021;S0305-4179(21)00311-9.
   PubMed Web of Science ®Google Scholar